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HFS 14: A SPECIFIC QUALITY OF LIFE INSTRUMENT FOR PATIENTS
WITH HAND-FOOT SYNDROME
Taieb C1, Sibaud V2
1Pierre Fabre, Boulogne, France, 2AVENE, LAVAUR, France
Hand-foot syndrome or palmar-plantar erythrodysesthesia is a common adverse effect
of certain chemotherapy agents, such as capecitabine or pegylated doxorubicin, where 
it is estimated to occur in 50% of cases. It is also frequently reported with some new
targeted anticancer therapies, such as sorafenib or sunitinib, although its clinical pre-
sentation is slightly different. OBJECTIVES: To develop and validate a hand-foot 
syndrome-speciﬁ c quality of life scale in order to be able to measure the impact of the 
condition on patients and to be able to assess the value of certain speciﬁ c treatments 
in this indication. METHODS: The questionnaire was developed after conducting a 
series of structured interviews with patients with forms of hand-foot syndrome of 
varying severity, which yielded a detailed and rigorous collection of verbatim tran-
scripts. RESULTS: Thirty-one items were identiﬁ ed, and 14 items were selected as
being relevant and non-overlapping after initial evaluation. The ﬁ rst question in the 
HFS14 addresses which member is affected (hand, foot or both). The second question 
addresses the pain with three possible responses (very, moderately or not painful). The
14 items can be organised in 2 modules: the ﬁ rst module more speciﬁ cally assesses the
handicap generated by involvement of the feet and the second assesses the handicap 
generated by involvement of the hands. Six items are considered common to both 
modules, four are hand-speciﬁ c and four are foot-speciﬁ c. Psychometric validation 
conﬁ rmed the internal consistency and very high reproducibility of the questionnaire.
CONCLUSIONS: The hand-foot syndrome-speciﬁ c HFS14 scale is easy to use and 
meets the requirements of a quality of life scale. This scale now needs to be tested in
longitudinal studies for example in clinical trials to conﬁ rm its ability to measure a 
change in status.
PCN83
A MULTINATIONAL STUDY OF PATIENT PREFERENCE VALUES FOR 
HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKEMIA
Szabo SM1, Davis C2, Cortes J3, Levy AR1
1Oxford Outcomes Ltd, Vancouver, BC, Canada, 2Bristol-Myers Squibb, Wallingford, CT, USA, 
3MD Anderson Cancer Center, Houston, TX, USA
OBJECTIVES: Studies of preferences in many disease areas show that patients
valuate health states higher than general public respondents. We previously elicited
general public preferences for chronic myelogenous leukemia (CML) health states.
The objectives here were to 1) estimate preferences for CML health states from
US, UK, Canadian, and Australian patients, and 2) determine if adjusted point esti-
mates of patient preferences for CML health states were higher than those of general 
public respondents. METHODS: Time trade-off preference values for six CML health
states were elicited from CML patients by trained interviewers using a script. Stan-
dardized health state descriptions were derived in consultation with a panel of oncolo-
gists. Mean health state preferences were calculated and a generalized linear model 
used to determine signiﬁ cant predictors. While statistical comparisons were not appro-
priate, point estimates of patient preferences were compared against known general
public preferences for CML health states. RESULTS: Ninety-three patients were
included, from the US (n  33, 35%), UK (n  11; 12%), Canada (n  24; 26%), and 
Australia (n  25; 27%). The mean age was 52 years (range, 20–79) and 60% were 
men. Signiﬁ cant differences were observed in mean patient preferences between the 
countries. After adjustment for country, age and sex, mean patient preferences were:
0.95 for chronic phase responding (CR); 0.76 for chronic phase non-responding
(CNR); 0.84 for accelerated phase responding (AR); 0.54 for accelerated phase 
non-responding (ANR); 0.38 for blast phase responding (BR); and 0.27 for blast 
phase non-responding (BNR). Except for BR, all point estimates of general public 
preferences were lower than patient values, and were: 0.91 (CR); 0.73 (CNR); 0.78 
(AR); 0.49 (ANR); 0.48 (BR); and 0.22 (BNR). CONCLUSIONS: This study provides 
evidence that preferences for oncological health states follow the pattern expected if 
habituation were taking place, and patients report higher preferences than general 
public representatives.
PCN84
VALIDATION OF THE EUROQOL EQ-5D IN PATIENTS WITH RELAPSED/
REFRACTORY MANTLE CELL LYMPHOMA (RR MCL)
Cuyun Carter G1, Liepa AM1, Zimmermann AH1, Morschhauser F2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Centre Hospitalier Universitaire, Lille, France
OBJECTIVES: Health utilities, measured by the EQ-5D, have not been reported 
for MCL, an aggressive form of non-Hodgkin’s lymphoma. This research aimed to
explore the validity of the EQ-5D in patients with RR MCL and to estimate minimally 
important differences (MIDs). METHODS: Data were collected in a phase II, single-
arm, open-label study of enzastaurin in RR MCL patients (Morschhauser et al, Ann 
Oncol 2008). Criterion validity was assessed by grouping patients by International
Prognostic Index (IPI) and by Eastern Cooperative Oncology Group performance
status (PS). Responsiveness to change was assessed by grouping patients according to
changes in PS (improved/stable or worse) and disease status. Distribution- and anchor-
based methods were used to estimate MIDs. RESULTS: EQ-5D data were available 
for 58 of 60 enrolled patients at baseline and for 38 patients at discontinuation. 
Median age was 66 years, 70% were male, 88% had a baseline PS of 0 or 1, and
52% had an IPI score a2. There was a statistically signiﬁ cant (p  0.05) difference in
baseline EQ-5D index (0.81, 0.63, 0.58) and visual analogue scale (VAS) (66.9, 56.4, 
44.7) by PS group (0, 1, 2, respectively) and at discontinuation by PS group for the 
index (0.77, 0.61, 0.28). There were no signiﬁ cant differences for the index or VAS
scores by IPI group. Those patients with worsened PS (n  12) had signiﬁ cantly worse
index and VAS scores than those patients with improved/stable PS (n  18). The 
estimated MID ranges across the varying methodologies were 0.05–0.10 for the 
index and 5.2–10.0 for the VAS. CONCLUSIONS: This retrospective study provides
evidence that the EQ-5D is a valid instrument to assess health status in patients with 
RR MCL, based on differentiation of patients by clinical status. The estimated MIDs
are consistent with those reported for other cancers and will be helpful in designing 
future studies.
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TESTING THE MEASUREMENT EQUIVALENCE OF PAPER 
AND INTERACTIVE VOICE RESPONSE (IVR) VERSIONS OF
THE EORTC QLQ-C30
Lundy JJ1, Coons SJ1, Aaronson NK2
1University of Arizona, Tucson, AZ, USA, 2The Netherlands Cancer Institute, Amsterdam, 
Netherlands
OBJECTIVES: When migrating existing patient-reported outcome measures to elec-
tronic data capture technologies, it is critically important that the new modes of 
administration provide comparable results to the original. The objective of this study
was to evaluate the measurement equivalence of an interactive voice response (IVR) 
version to the original paper-based version of the EORTC QLQ-C30. METHODS:
The QLQ-C30 is a cancer-speciﬁ c health-related quality of life measure consisting of 
nine multi-item scales (physical, role, emotional cognitive and social functioning, 
fatigue, emesis and global health/quality of life) and six single item measures (dyspnoea,
insomnia, appetite loss, constipation, diarrhoea, and ﬁ nancial problems). This study 
utilized a crossover design with subjects randomly assigned to one of two assessment
orders: 1) paper then IVR, or 2) IVR then paper. Cancer patients receiving treatment
on an outpatient basis (n  139) were asked to complete each assessment two days 
apart. Equivalence between the two administration modes was established by compar-
ing the 95% lower conﬁ dence interval (CI) of the intraclass correlation coefﬁ cients 
(ICCs) for each scale, with a critical value of 0.70. RESULTS: The ICCs for the nine 
multi-item scales were all above 0.79, ranging from 0.791 to 0.899 (ICC 95% lower
CI range: 0.726 to 0.865), and signiﬁ cantly different from our threshold reliability of 
0.70. The ICCs for the six single items ranged from 0.689 to 0.896 (ICC 95% lower 
CI range: 0.611 to 0.888). Two of the items, insomnia and appetite loss, were not sta-
tistically different from 0.70. Thus, we do not denote equivalence based on the ICCs
for these two items. However, when taken together, the results support the equivalence
of the scores between the paper and IVR versions of the QLQ-C30. CONCLUSIONS:
This analysis provides evidence that the scores obtained from the IVR version of the 
QLQ-C30 are equivalent to those obtained with the original paper version.
PCN86
TEST-RETEST RELIABILITY OF AN INTERACTIVE VOICE RESPONSE (IVR)
VERSION OF THE EQ-5D IN A SAMPLE OF CANCER SURVIVORS
Lundy JJ, Coons SJ
University of Arizona, Tucson, AZ, USA
OBJECTIVES: The objective of this study was to assess the test-retest reliability of an 
interactive voice response (IVR) version of the EQ-5D. METHODS: The EQ-5D self-
report questionnaire consists of a descriptive system and a visual analog scale (EQ
VAS). Responses on the descriptive system classify the respondent into one of 243 
unique health states. A preference weight is assigned to the health state, resulting in
an EQ-5D index score on a scale where 1  perfect health and 0  death. Cancer clinic 
patients (n  127) were asked to complete the IVR-based EQ-5D twice, two days
apart. The analyses tested for mean differences (paired t-test) and test-retest reliability 
(ICC) to assess measurement stability over time. Equivalence of the means was estab-
lished if the 95% conﬁ dence interval (CI) was within the minimally important differ-
ence (MID) interval, namely .025 to .025 for the index and 3 to 3 for the EQ-VAS. 
Adequacy of the ICC was established by comparing the ICC 95% lower CI with a 
critical value of 0.70. RESULTS: Both administrations were completed per protocol 
by 110 subjects (EQ-5D index) and 114 subjects (EQ VAS). For the EQ-5D index, the
means (SD) of the ﬁ rst and second administrations were 0.871 (0.138) and 0.868
(0.153), respectively. The 95% CI of the mean difference was 0.012 to 0.017, which 
was within the equivalence interval. The ICC was 0.858 (0.800 – 0.901) and was sig-
niﬁ cantly different from 0.70 (p  0.001). For the EQ VAS, the means (SD) were 81.34
(17.46) and 80.83 (17.52), respectively. The 95% CI of the mean difference was 
0.598 to 1.617, which was within the equivalence interval. The ICC was 0.944
(0.919 – 0.961) and was signiﬁ cantly different from 0.70 (p  0.001). CONCLU-
SIONS: This analysis provides substantial evidence that the scores obtained from the 
IVR version of the EQ-5D are reliable upon repeated administrations.
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TEST-RETEST RELIABILITY OF AN INTERACTIVE VOICE 
RESPONSE (IVR) VERSION OF THE EORTC QLQ-C30
Lundy JJ1, Coons SJ1, Aaronson NK2
1University of Arizona, Tucson, AZ, USA, 2The Netherlands Cancer Institute, Amsterdam, 
Netherlands
OBJECTIVES: The objective of this study was to assess the test-retest reliability of 
an interactive voice response (IVR) version of the EORTC QLQ-C30. METHODS: A 
convenience sample of outpatient cancer clinic patients (n  127) was asked to com-
plete the IVR version of the QLQ-C30 twice, two days apart. The QLQ-C30 is a 30-
item, cancer-speciﬁ c questionnaire composed of single-items and multi-item scales. The 
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instrument has ﬁ ve functional scales (physical, role, cognitive, emotional, and social), 
three symptom scales (fatigue, pain, and emesis), and a global health/quality of life 
scale. The remaining single items assess dyspnoea, appetite loss, sleep disturbance,
constipation, and diarrhoea. The analyses focused on intraclass correlation coefﬁ cients 
(ICCs), comparing the ICC 95% lower conﬁ dence interval with a critical value of 
0.70. RESULTS: Subjects who did not complete the second assessments within 72 
hours or who had score differences on the scales or items exceeding two standard
deviations were excluded from the per protocol analyses. The sample sizes used in the
per protocol analyses ranged from 112 to 115 subjects. The ICCs for the 9 multi-item
scales were all above 0.69, ranging from 0.698 to 0.926 (ICC 95% lower CI range:
0.608 to 0.901). All of the scales were signiﬁ cantly different from our threshold reli-
ability of 0.70, with the exception of the cognitive functioning scale. The ICCs for the
6 single items ranged from 0.782 to 0.908 (ICC 95% lower CI range: 0.714 to 0.876) 
and all were statistically different from 0.70. The evidence supports the stability of 
the scores obtained on the IVR version of the QLQ-C30 upon repeated measurement. 
CONCLUSIONS: The equivalence of the IVR and paper versions of the QLQ-C30
has been demonstrated elsewhere. This analysis provides additional evidence of the
test-retest reliability of the IVR version of the QLQ-C30.
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LEVERAGING PATIENT-REPORTED OUTCOMES TO DEFINE
FATIGUE IN CANCER
Scott J1, Piault E2, Lasch KE2, Jernigan KA2
1Mapi Values, Macclesﬁ eld, Cheshire, UK, 2Mapi Values, LLC, Boston, MA, USA
OBJECTIVES: Research indicates 18% to 96% of cancer patients experience fatigue
due to cancer or its treatment. Only one claim for “cancer-related fatigue” (CF) has
been granted by the US Regulatory Authorities. To date, the deﬁ nition or diagnosis
of CF remains a subject for debate within the clinical community. Although several
self-completed CF-speciﬁ c instruments are available, the lack of an accepted concep-
tual framework articulating those concepts important to patients has hampered 
research in this ﬁ eld. Developing a preliminary conceptual framework able to underpin
patients’ experience of CF is central to gather meaningful data. Qualitative articles 
with verbatim patient quotes were reviewed and synthesized to begin a large effort 
to develop such a framework. METHODS: A systematic search identiﬁ ed 95 articles 
published between 1996 and 2007 containing patient quotes. Search terms included
fatigue, tiredness, lassitude, weakness, or asthenia. Two researchers independently 
reviewed articles; 645 quotes were extracted and systematically analyzed to identify 
concepts and language used to describe patients’ CF experiences. RESULTS: CF is 
more intense than pre-diagnosis or treatment tiredness. Terms such as “overwhelm-
ing,” “unusual,” and “all-encompassing” were used to describe CF. Quotes referring
to “tiredness” were often associated with adverbs (very, extremely) or patients’ idi-
omatic phrases intensifying “tiredness” (e.g., “dead-tired”, “sick-tired”) to distinguish 
tiredness due to CF. Metaphors depicted the severity and debility associated with CF. 
CONCLUSIONS: Findings suggest that extant CF assessments fail to capture the 
unique experience of CF as described by patients. Publication bias and lack of primary
data from which quotes were drawn are study limitations. Rigorous qualitative 
research with patients with different types and stages of cancer is needed to concisely
and comprehensively describe the experience of CF and its impact.
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FACTORS IMPACTING THE HEALTH RELATED QUALITY
OF LIFE IN FEMALE BREAST CANCER PATIENTS – 
AN OBSERVATIONAL, CROSS-SECTIONAL STUDY
Cristino J, Piercy J, Worsfold A
Adelphi Group, Bollington, Cheshire, UK
OBJECTIVES: To estimate the impact of performance status (ECOG), age, concomi-
tant conditions, length of diagnosis, exposure to chemotherapy treatment and care-
giver need on health related quality of life (HRQoL) in 800 adult female breast cancer
patients in the USA and 5 European countries (France, Germany, Italy, Spain and UK). 
METHODS: Data were drawn from the Adelphi Breast Cancer Disease Speciﬁ c Pro-
gramme (DSP), a cross-sectional study of consulting patients, undertaken in 2007. 
Physicians collected data on the next 7 patients presenting with breast cancer during
the study period. Patients were asked to report on their HRQoL (FACT-B). OLS 
regressions were performed using STATA. Diagnostic tests were performed (joint sig-
niﬁ cance, misspeciﬁ cation and multicolinearity) and White standard errors were
applied. RESULTS: Eight hundred (Europe, 686; USA, 114) patient records were 
analysed. FACT-B scores were signiﬁ cantly impacted in line with worsening ECOG
performance status (Grade 1: 7.44, overall; 5.94, USA; 13.48, Europe; all p 
0.001: Grade 2: 14.92, overall; 13.45, USA; 19.39, Europe; all p  0.001: Grade
3: 22.04, overall; 20.87, USA; 21.94, Europe; all p  0.001, except USA, p  0.05).
No Grade 4 patients were present in the sample. FACT-B scores were lower overall 
and in Europe, in patients currently receiving chemotherapy (-9.13, overall; 9.78,
Europe; all p  0.001), those with a caregiver (5.64, overall; 7.05, Europe; all p 
0.001). Longer diagnosis (0.82, P  0.05) and presence of mental health related 
concomitant conditions (7.25, P  0.05) were signiﬁ cant in US patients only. Age and
heart related concomitant conditions were not signiﬁ cant. Models showed overall
robustness to the diagnostic tests performed. CONCLUSIONS: A signiﬁ cant associa-
tion was seen between the patient-reported FACT-B scores and the physician-reported 
ECOG performance status. The impact of the various factors identiﬁ ed, including 
chemotherapy use, mental health related concomitant conditions and time since diag-
nosis, can provide useful indicators to be taken into account in the management of 
breast cancer patients.
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A METHODOLOGICAL INVESTIGATION TO DEFINE A
CLINICALLY RELEVANT CUT-OFF POINT IN THE ORDINAL
SCALE OF THE EORTC QLQ-C30 QUESTIONNAIRE
Quinten C1, Martinelli F1, Coens C1, Maringwa J1, Cleeland C2, Fechtner H3, Gotay C4, 
Greimel E5, King M6, Osoba D7, Taphoorn MJB8, Reeve B9, Ringash J10, 
Schmucker-Von Koch J11, Weis J12, Bottomley A1
1EORTC, Brussels, Belgium, 2U.T.M.D. Anderson Cancer Center, Houston, TX, USA, 3City 
Hospital Magdeburg, Magdeburg, Germany, 4University of British Columbia, Vancouver, BC, 
Canada, 5Medical University Graz, Graz, Austria, 6University of Sydney, Sydney, Australia, 
7QOL Consulting, West Vancouver, BC, Canada, 8VU University Medical Center/Medical 
Center Haaglanden, Den Haag, Netherlands, 9National Cancer Institute, Bethesda, MD, USA, 
10The Princess Margaret Hospital, Toronto, ON, Canada, 11University of Regensburg, 
Regensburg, Germany, 12University of Freiburg, Freiburg, Germany
OBJECTIVES: The objective of this analysis was to develop a new analytic methodol-
ogy to identify a clinically relevant cut-off point in the EORTC QLQ-C30 ordinal
pain score by comparing patient and clinician reporting for the same symptom. Ability 
to translate between clinician and patient reported symptoms will be useful in planned 
future analyses. METHODS: Closed European Organisation for Research and Treat-
ment of Cancer Randomized Controlled Trials, where the symptom pain was scored
at baseline by the patient (EORTC QLQ-C30) and the clinician [Common Toxicity
Criteria (CTC)], were pooled and analysed to test the optimal cut-off point. The CTC 
was dichotomized as 0,1,2 vs. 3,4; deﬁ ned as a clinical relevant cut-off point for clini-
cal practice. Percent agreement with various dichotomizations of the QLQ-C30 pain 
scale was calculated, and McNemar’s test applied. Veriﬁ cation of the accuracy and 
generalizibility of the ﬁ ndings was evaluated with a validation set and by applying the 
same cut-off point on another symptom, i.e. fatigue. RESULTS: Data were available 
for pain [number of trials (t)  8, number of patients (n)  1214] and fatigue [t  5, 
n  1237]. Model and validation set were obtained by splitting the dataset in half.
Percentage agreement and p values for McNemar tests, between patient and clinician 
dichotomized scores using different cut-off points for the QLQ-scale, were: median 
(2.19 vs. 2.19, 64%, p  .01), quartile (vs. 3.0, 81%, p  0.55), decile (4.0 vs. 
4.0, 85%, p  0.01). The quartile split reﬂ ects best the dichotomized CTC score. This 
was conﬁ rmed in the validation set (quartile cut-off point: 82%, p  0.86). However, 
when the quartile cut-off was applied to the QLQ-C30 fatigue scale, a signiﬁ cant dif-
ference (p  .01) between patient and clinician results was found. CONCLUSIONS:
Our results indicate that a quartile split of the QLQ-C30 pain score is optimal. 
However, a single cut-point may not generalize to other QLQ-C30 symptoms;
symptom-speciﬁ c cut-points may be required.
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PROVISION OF QUALITY OF LIFE INFORMATION AND
PHYSICIAN TRUST AMONG FAMILIES OF CHILDREN WITH
LIFE-LIMITED CONDITIONS
Huang IC, Knapp C, Shenkman E
University of Florida, Gainesville, FL, USA
OBJECTIVES: To examine what information that parents of children with life-limiting 
conditions want from physicians and whether the provision of this information pro-
motes parents’ trust in physicians. METHODS: We conducted telephone surveys from
November 2007 through April 2008 with a random sample of 266 parents whose
children had life-limiting conditions and enrolled in Florida’s State Title V Children 
with Special Health Care Needs Program. Parents were asked if they wanted informa-
tion about the following: the child’s quality of life, pain relief, prognosis, incorporating
spiritual beliefs into the treatment plan, how treatments might change the child’s
appearance, and clinical examination/laboratory results. We used the Wake Forest
Physician Trust Scale to measure parent’s trust in physicians. We tested the relation-
ships between parent’s age, race/ethnicity, education, marital status, and parent-
reported children’s health status and desired information. We also tested whether
provision of this desired information was associated with greater trust in physicians.
RESULTS: Most parents wanted information on their children’s quality of life (95%), 
followed by the prognosis (88%) and pain relief (84%). Forty-nine percent of the 
parents desired advice from family/friends. Compared to parents with a high school 
education or higher, parents with less than a high school education showed a greater 
desire for information on pain relief and spiritual belief (p  0.05). Compared to White 
non-Hispanic parents, Hispanic and Black non-Hispanic parents showed a greater
desire for information on the child’s prognosis, incorporating spiritual beliefs into the
treatment plan, and the impact of the treatment on the child’s appearance (p  0.05). 
Providing information on children’s quality of life and pain relief was associated with 
greater trust in physicians after adjusting for parental characteristics (p  0.05). 
CONCLUSIONS: Parents wanted information on their children’s quality of life more 
so than any other information category. Providing this information along with infor-
mation about pain relief increased the families’ trust in the physicians.
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HOW DOES TRUST IN PHYSICIANS AFFECT PARENTS’ 
TREATMENT DECISION MAKING FOR THEIR CHILDREN
WITH LIFE-LIMITING CONDITIONS?
Huang IC, Knapp C, Shenkman E
University of Florida, Gainesville, FL, USA
OBJECTIVES: To examine the association between characteristics of parents whose 
children are diagnosed with life-limiting conditions, trust in physicians, and problems
in the shared decision making process. METHODS: This study using data collected 
